RxDoctor Payments Data

Kari Clouse, MD

Family Medicine · Andover, KSNPI 1962636944

Payments from drug & device makers

$11,547in general payments, 2019–2025

Across 795 payments — averaging $14.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$1K
  • AstraZeneca$824
  • Astellas Pharma US Inc$794
  • Novo Nordisk$779
  • Amgen$724
  • plus $5K from 47 others

What the payments were for

  • Food & beverage$11,522100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,547 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$76,755
Medicare patients
215
Services billed
3,301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide49$51,272
OzempicSemaglutide44$40,046
JardianceEmpagliflozin37$31,671
EliquisApixaban48$28,766
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$20,284
Bydureon BciseExenatide Microspheres19$15,163
TrulicityDulaglutide11$10,890
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,433
Repatha SyringeEvolocumab12$6,620
LinzessLinaclotide12$6,596
SynthroidLevothyroxine Sodium32$2,971
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen92$2,031
Tizanidine Hcl34$1,946
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$1,778
Levothyroxine Sodium193$1,655

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,182$62,16260 claims
Novo NordiskOzempic$779$40,04644 claims
Boehringer IngelheimJardiance$155$31,67137 claims
PfizerEliquis$413$28,76648 claims
GSKTrelegy Ellipta$537$20,28431 claims
AbbVieLinzess, Synthroid$2,012$9,56644 claims
AstraZenecaBreztri Aerosphere$824$9,43315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Andover

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →